| dc.contributor | 科管智財所 | zh_TW |
| dc.creator (作者) | 陳秉訓 | zh_TW |
| dc.creator (作者) | Chen, Ping-Hsun | en_US |
| dc.date (日期) | 2017-07 | |
| dc.date.accessioned | 17-May-2018 16:47:50 (UTC+8) | - |
| dc.date.available | 17-May-2018 16:47:50 (UTC+8) | - |
| dc.date.issued (上傳時間) | 17-May-2018 16:47:50 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/117183 | - |
| dc.description.abstract (摘要) | The Trans-Pacific Partnership (“TPP”) Agreement mandates member states to implement a patent linkage system vested in Article 18.53. To successfully join the TPP Agreement, Taiwan has begun the legislation of a patent linkage system by proposing an amendment for the Pharmaceutical Affairs Act. Article 18.53 requires a member either to adopt a notification mechanism under Paragraph 1 or to stay the issuance of marketing approval under Paragraph 2. But, Taiwan’s proposal includes both measures. Taiwan’ patent linkage system allows a pioneer drug company to register patents claiming (a) a material; (b) a combination or formula; or (c) pharmaceutical use. The scope of patentees who may benefit from the mechanism is larger than what is required. In addition, the system requires a generic drug company to notify the patentee at the time of filing the drug application if the generic drug company asserts invalidity or non-infringement which the generic drug company must prove. Furthermore, the health authority is allowed to stay the issuance of a generic drug permit while the patentee is suing the generic drug company in the court. | en_US |
| dc.format.extent | 648776 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Journal of Law and Health, Vol.30, No.1, pp.55-79 | zh_TW |
| dc.title (題名) | Analysis of the Proposed TPP-Related Patent Linkage System in Taiwan | en_US |
| dc.type (資料類型) | article | |
